Drs Banu Arun and Kevin Kalinsky discuss immunotherapy in the treatment of advanced and metastatic breast cancer, including recent studies, side effects, access to treatment, and disparities in care.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982648). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34914339/

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33030848/

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30345906/

Primary Results From IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel With or Without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34219000/

Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33278935/

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03) https://clinicaltrials.gov/ct2/show/NCT05382299

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) https://clinicaltrials.gov/ct2/show/NCT05382286

Datopotamab Deruxtecan, a Novel TROP2-Directed Antibody-Drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum Treated Advanced Triple-negative Breast Cancer (DORA) (DORA) https://clinicaltrials.gov/ct2/show/NCT03167619

A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) https://pubmed.ncbi.nlm.nih.gov/30563931/

Pembrolizumab for Early Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/